The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
Recent Posts
- This ETF provider launches a new way to play Tesla
- Bitcoin soared in 2024. How much — if any — should you own?
- Dow tumbles nearly 700 points Friday as strong jobs report casts doubt over Fed’s rate-cut path
- TikTok ban likely to be upheld by Supreme Court, putting pressure on Trump
- Apple’s market share slides in China as iPhone shipments decline, analyst Kuo says